Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2)

Authors

Uttam K. Rao, Brian G. Engelhardt^*

Department of Medicine, Vanderbilt University Medical Center, Medical Center Drive, Nashville, TN, USA

^*Corresponding author. Tel.: 615-936-0381, Fax: 615-936-1812. Email: brian.engelhardt@vumc.org

DOI

10.2991/chi.d.200506.002How to use a DOI?

Keywords

ST2; IL-33; PTDM

Abstract

Patients undergoing allogeneic hematopoietic cell transplantation (HCT) are at risk for numerous acute and long-term complications from this procedure. Post-transplant diabetes mellitus (PTDM) is a common but under-recognized problem. Similar to graft-versus-host disease (GVHD), new-onset diabetes is characterized by immune dysregulation that can negatively impact transplant outcomes. This review will discuss the biology of IL-33/ST2 in acute GVHD and PTDM development, and how this cytokine axis could be leveraged for predicting and treating immuno-metabolic complications after transplant.

Copyright

© 2020 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.

Open Access

This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

TY  - JOUR
AU  - Uttam K. Rao
AU  - Brian G. Engelhardt
PY  - 2020
DA  - 2020/05/21
TI  - Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2)
JO  - Clinical Hematology International
SP  - 101
EP  - 108
VL  - 2
IS  - 3
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.200506.002
DO  - 10.2991/chi.d.200506.002
ID  - Rao2020
ER  -